Clinical trial · Interventional
The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery
The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery, a Randomised Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Thoracal paravertebral block (TPVB) is a commonly prefferred regional anesthesia technique to provide postoperative analgesia. In addition, the successful use of TPVB is reported for some seroma related pain cases. Postoperative analgesia in breast surgery is a difficult and overworked issue due to etensive surgery and complex innervation of the breast and in addition to this complex mechanisms, seroma accumulation has a negative effect for patients postoperatively. With this study, the investigators aimed to study the effect of TPVB on seroma reduction for breast cancer surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Seroma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thoracal paravertebral block | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control Group
- description
- No intervention will be applied to control group
- type
- EXPERIMENTAL
- label
- TPVB group
- description
- Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
- interventionNames
- Procedure: Thoracal paravertebral block
Primary outcomes (1)
- measure
- Seroma quantitiy
- timeFrame
- 24 hour postoperatively.
- description
- Seroma quantitiy of all patients will be recorded after 24 hour postoperatively.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * 18-70 years of agge * ASA I-II * Undergoing elective breast cancer surgery Exclusion Criteria: * obesity (body mass index \>35 kg/m2) * infection of the skin at the site of needle puncture area * patients with known allergies to any of the study drugs * coagulopathy
References
Publications (0)
Data not yet available